CN103275223A - 降钙素原抗体的制备方法 - Google Patents
降钙素原抗体的制备方法 Download PDFInfo
- Publication number
- CN103275223A CN103275223A CN2013102163865A CN201310216386A CN103275223A CN 103275223 A CN103275223 A CN 103275223A CN 2013102163865 A CN2013102163865 A CN 2013102163865A CN 201310216386 A CN201310216386 A CN 201310216386A CN 103275223 A CN103275223 A CN 103275223A
- Authority
- CN
- China
- Prior art keywords
- procalcitonin
- preparation
- antibody
- primer
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010048233 Procalcitonin Proteins 0.000 title claims abstract description 110
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 title claims abstract description 92
- 238000000034 method Methods 0.000 title claims abstract description 8
- 239000013612 plasmid Substances 0.000 claims abstract description 26
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 18
- 230000014509 gene expression Effects 0.000 claims abstract description 17
- 239000013604 expression vector Substances 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims description 30
- 239000013600 plasmid vector Substances 0.000 claims description 25
- 230000004544 DNA amplification Effects 0.000 claims description 23
- 239000012634 fragment Substances 0.000 claims description 22
- 108090000790 Enzymes Proteins 0.000 claims description 21
- 102000004190 Enzymes Human genes 0.000 claims description 21
- 241000894006 Bacteria Species 0.000 claims description 19
- 108091008146 restriction endonucleases Proteins 0.000 claims description 19
- 238000013467 fragmentation Methods 0.000 claims description 15
- 238000006062 fragmentation reaction Methods 0.000 claims description 15
- 238000012216 screening Methods 0.000 claims description 12
- 239000003643 water by type Substances 0.000 claims description 12
- 230000008859 change Effects 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 238000013016 damping Methods 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 8
- 238000012408 PCR amplification Methods 0.000 claims description 7
- 238000005520 cutting process Methods 0.000 claims description 7
- 241000235648 Pichia Species 0.000 claims description 6
- 238000000855 fermentation Methods 0.000 claims description 6
- 230000004151 fermentation Effects 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- 230000003321 amplification Effects 0.000 claims description 5
- 230000029087 digestion Effects 0.000 claims description 5
- 210000004408 hybridoma Anatomy 0.000 claims description 5
- 230000000968 intestinal effect Effects 0.000 claims description 5
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 5
- 238000000246 agarose gel electrophoresis Methods 0.000 claims description 4
- 238000000137 annealing Methods 0.000 claims description 4
- 230000004087 circulation Effects 0.000 claims description 4
- 238000003752 polymerase chain reaction Methods 0.000 claims description 4
- 239000000376 reactant Substances 0.000 claims description 4
- 102000003960 Ligases Human genes 0.000 claims description 3
- 108090000364 Ligases Proteins 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 230000007850 degeneration Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 238000010367 cloning Methods 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 230000002035 prolonged effect Effects 0.000 claims description 2
- 230000024835 cytogamy Effects 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 15
- 206010040047 Sepsis Diseases 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 6
- 108060001064 Calcitonin Proteins 0.000 description 5
- 102000055006 Calcitonin Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 238000003748 differential diagnosis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 108010064381 preprocalcitonin Proteins 0.000 description 2
- 230000009465 prokaryotic expression Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102100036826 Aldehyde oxidase Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 101800003632 Katacalcin Proteins 0.000 description 1
- 102400000112 Katacalcin Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 101000924393 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Vacuolar aminopeptidase 1 Proteins 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108091006374 cAMP receptor proteins Proteins 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- BOARIOLZPFSAQJ-NQSKQZERSA-N katacalcin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](OC)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)C(CC=1NC=NC=1)NC(=O)C(CC(O)=O)NC(=O)C(CCCNC(N)=N)NC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)C(CO)NC(=O)C(CCSC)NC(=O)[C@@H](N)CC(O)=O)C1=CN=CN1 BOARIOLZPFSAQJ-NQSKQZERSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008718 systemic inflammatory response Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310216386.5A CN103275223B (zh) | 2013-06-04 | 2013-06-04 | 降钙素原抗体的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310216386.5A CN103275223B (zh) | 2013-06-04 | 2013-06-04 | 降钙素原抗体的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103275223A true CN103275223A (zh) | 2013-09-04 |
CN103275223B CN103275223B (zh) | 2015-06-17 |
Family
ID=49057861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310216386.5A Active CN103275223B (zh) | 2013-06-04 | 2013-06-04 | 降钙素原抗体的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103275223B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104090109A (zh) * | 2014-07-25 | 2014-10-08 | 胡晓武 | 快速检测人血降钙素原胶体金免疫层析试纸及其检测方法 |
CN104531715A (zh) * | 2014-10-27 | 2015-04-22 | 西北工业大学 | 人降钙素原重组表达、单、多克隆抗体的制备及elisa检测方法 |
CN104610443A (zh) * | 2015-02-16 | 2015-05-13 | 中国人民解放军军事医学科学院基础医学研究所 | 一种高稳定性重组降钙素原、制备方法及用途 |
CN105732810A (zh) * | 2016-03-04 | 2016-07-06 | 宁波美康生物科技股份有限公司 | 一种降钙素原单克隆抗体及其应用 |
CN112940120A (zh) * | 2021-05-14 | 2021-06-11 | 深圳海创生物技术有限公司 | 降钙素原单域抗体及其应用和试剂盒 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108084256A (zh) * | 2017-12-28 | 2018-05-29 | 北京市华信行生物科技有限公司 | 降钙素原突变体及其制备方法和用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1984001173A1 (en) * | 1982-09-15 | 1984-03-29 | Immuno Nuclear Corp | Production of mature proteins in transformed yeast |
US6905687B2 (en) * | 1999-12-22 | 2005-06-14 | Dade Behring Marburg Gmbh | Human procalcitonin and the preparation and use thereof |
-
2013
- 2013-06-04 CN CN201310216386.5A patent/CN103275223B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1984001173A1 (en) * | 1982-09-15 | 1984-03-29 | Immuno Nuclear Corp | Production of mature proteins in transformed yeast |
US6905687B2 (en) * | 1999-12-22 | 2005-06-14 | Dade Behring Marburg Gmbh | Human procalcitonin and the preparation and use thereof |
Non-Patent Citations (3)
Title |
---|
董慧敏: "降钙素原的克隆表达及鉴定", 《广东医学》 * |
谭倩: "降钙素原基因克隆表达及多克隆抗体的制备", 《细胞与分子免疫学杂志》 * |
陈跃瑜: "降钙素原的克隆、表达及多抗制备", 《热带医学杂志》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104090109A (zh) * | 2014-07-25 | 2014-10-08 | 胡晓武 | 快速检测人血降钙素原胶体金免疫层析试纸及其检测方法 |
CN104531715A (zh) * | 2014-10-27 | 2015-04-22 | 西北工业大学 | 人降钙素原重组表达、单、多克隆抗体的制备及elisa检测方法 |
CN104610443A (zh) * | 2015-02-16 | 2015-05-13 | 中国人民解放军军事医学科学院基础医学研究所 | 一种高稳定性重组降钙素原、制备方法及用途 |
CN105732810A (zh) * | 2016-03-04 | 2016-07-06 | 宁波美康生物科技股份有限公司 | 一种降钙素原单克隆抗体及其应用 |
CN105732810B (zh) * | 2016-03-04 | 2019-03-12 | 美康生物科技股份有限公司 | 一种降钙素原单克隆抗体及其应用 |
CN112940120A (zh) * | 2021-05-14 | 2021-06-11 | 深圳海创生物技术有限公司 | 降钙素原单域抗体及其应用和试剂盒 |
CN112940120B (zh) * | 2021-05-14 | 2021-08-17 | 深圳海创生物技术有限公司 | 降钙素原单域抗体及其应用和试剂盒 |
Also Published As
Publication number | Publication date |
---|---|
CN103275223B (zh) | 2015-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103275223B (zh) | 降钙素原抗体的制备方法 | |
CN111153991A (zh) | 一种人SARS-CoV-2单克隆抗体及其制备方法和应用 | |
CN101942416B (zh) | 抗人心肌肌钙蛋白i特异性单克隆抗体及其制备方法 | |
CN104650195B (zh) | Ev71病毒vp1重组抗原及其单克隆抗体与应用 | |
CN113980145B (zh) | 一种结核分枝杆菌融合蛋白及其制备方法和应用 | |
CN102964435B (zh) | 截短型溶血链球菌溶菌素o及利用其的检测试剂盒 | |
CN103304666A (zh) | 一种降钙素原单克隆抗体及其应用 | |
CN115109131B (zh) | 一种多克隆抗体在制备鉴别微孢子虫试剂中的应用 | |
CN101302526A (zh) | 重组可溶性溶血链球菌溶血素o基因、重组蛋白及其制备方法 | |
CN102643835A (zh) | 大鲵虹彩病毒主衣壳蛋白的原核表达及多抗制备和应用 | |
CN102004150A (zh) | 基于重组ul51蛋白的鸭瘟病毒抗体的检测方法 | |
CN102702324B (zh) | 人降钙素原b细胞表位肽段及其单克隆抗体的应用 | |
CN103833849A (zh) | Esat6-cfp10抗体的制备方法及其应用 | |
CN105524177A (zh) | 结核分枝杆菌特异性融合蛋白及其编码基因与应用 | |
CN112225781B (zh) | 一种表达新型冠状病毒n蛋白的方法 | |
CN104531715A (zh) | 人降钙素原重组表达、单、多克隆抗体的制备及elisa检测方法 | |
CN110894236B (zh) | 一种抗曲霉菌半乳甘露聚糖的单克隆抗体及其应用 | |
CN102533666A (zh) | 一种羊口疮病毒蛋白orfv059单克隆抗体杂交瘤g3及单克隆抗体 | |
CN113462675A (zh) | 一种ApuA蛋白抗原多肽及应用 | |
CN110205336A (zh) | 一种Brevinin-2GUb多肽的重组表达方法及应用 | |
CN101979406B (zh) | 南非ⅱ型口蹄疫多抗原表位蛋白、其制备方法及应用 | |
CN104292310B (zh) | 鸭瘟病毒UL15基因exonI重组蛋白及其制备方法和应用 | |
CN109134653A (zh) | 一种降钙素原抗体的制备方法 | |
CN108165569A (zh) | 一种快速检测弓形虫的重组蛋白及其制备方法和应用 | |
CN114957487B (zh) | 一种重组结核分枝杆菌融合蛋白及其在结核诊断中应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Method for preparing procalcitonin antibody Effective date of registration: 20170601 Granted publication date: 20150617 Pledgee: China Everbright Bank Limited by Share Ltd. Fuzhou branch Pledgor: FUJIAN HONGCHENG BIOLOG MEDICI Registration number: 2017350000068 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PP01 | Preservation of patent right | ||
PP01 | Preservation of patent right |
Effective date of registration: 20191023 Granted publication date: 20150617 |
|
PD01 | Discharge of preservation of patent | ||
PD01 | Discharge of preservation of patent |
Date of cancellation: 20221023 Granted publication date: 20150617 |
|
PP01 | Preservation of patent right | ||
PP01 | Preservation of patent right |
Effective date of registration: 20221023 Granted publication date: 20150617 |